Biomol Research Laboratoryt

Company Information

Company Name
Biomol Research Laboratoryt
Address
5166 Campus Drive
Plymouth Meeting, PA, 19462
Phone
n/a
URL
n/a
DUNS
n/a
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$299,834.00
6
Chart code to be here

Award List

  1. THE GOAL OF THIS RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR LEUKOTRIENE E4 AND LEUKOTRIENE E4-N-ACETATE, TWO IMPORTANT METABOLITES OF LEUKOTRIENE C4 AND D4.

    Amount: $50,000.00

    THE GOAL OF THIS RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR LEUKOTRIENE E4 AND LEUKOTRIENE E4-N-ACETATE, TWO IMPORTANT METABOLITES OF LEUKOTRIENE C4 AND D4. THESE LEUK ...

    SBIR Phase I 1986 Department of Health and Human Services
  2. RADIO IMMUNOASSAY KITS FOR PLATELET ACTIVATING FACTOR

    Amount: $50,000.00

    THE GOAL OF THE PROPOSED RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR PLATELET ACTIVATING FACTOR (PAF). PAF IS A LIPID MEDIATOR PRODUCED BY A VARIETY OF INFLAMMATORY CEL ...

    SBIR Phase I 1988 Department of Health and Human Services
  3. NOVEL THERAPEUTIC AGENT FOR MYOCARDIAL INFARCTION

    Amount: $50,000.00

    THE GOAL OF THIS RESEARCH IS TO DEVELOP A POTENT AND SPECIFIC PHARMACOLOGICALLY USEFUL ANTAGONIST TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR FOR USE AS A NEW THERAPEUTIC AGENT IN MYOCARDIAL INFARCTION. LTB ...

    SBIR Phase I 1990 Department of Health and Human Services
  4. NOVEL ANTICANCER DRUGS BASED ON GLYCOLIPID DEPLETION

    Amount: $50,000.00

    THE GOAL OF THE RESEARCH IS TO DEVELOP A POTENT PHARMACOLOGICALLY USEFUL INHIBITOR OF GLYCOSPHINGOLIPID (GSL) BIOSYNTHESIS. GSLS PLAY IMPORTANT ROLES IN (1) CANCER CELL METASTASIS, PROLIFERATION, AND ...

    SBIR Phase I 1992 Department of Health and Human Services
  5. Farnesyltransferase Inhibitors As Anticancer Agents

    Amount: $50,000.00

    The goal of the research is to develop a potent, pharmacologically useful inhibitor of farnesyltransferase for use as a new therapeutic agent for cancer. The Ras family of oncogenes and proto-oncogene ...

    SBIR Phase I 1993 Department of Health and Human Services
  6. Tyrosine Phosphatase Inhibitors As New Immunomodulators

    Amount: $49,834.00

    The goal of the research is to develop a potent pharmacologically useful inhibitor of the CD45 protein tyrosine phosphatase. CD45 is a transmembrane protein having a highly glycosylated extracellular ...

    SBIR Phase I 1993 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government